GLP-1 receptor agonists (GLP-1 RAs) have redefined the standard of care for type 2 diabetes (T2D), especially in patients with cardiovascular disease (CVD), chronic kidney disease (CKD), obesity, or metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis (MASLD/MASH). These innovative therapies …
Underserved patient populations often face significant health disparities rooted in unaddressed social drivers of health (SDOH), such as food insecurity, housing instability, and limited access to care. These social needs directly contribute to poor health outcomes and preventable health complications. …
There is a critical and ongoing need to educate nurses and nurse practitioners, who often form the backbone of patient care delivery, about the presence and impact of unconscious bias in clinical settings. As essential connectors within the healthcare provider …
Despite guideline familiarity and awareness of lipid-lowering targets, many clinicians fail to translate this knowledge into clinical action, leaving patients at elevated risk for cardiovascular events. A key driver of this disconnect is therapeutic inertia—particularly regarding risk assessment, intensification of …
GLP-1 receptor agonists (GLP-1 RAs) have become a cornerstone of type 2 diabetes (T2D) treatment, with strong endorsements from the American Diabetes Association and the American Association of Clinical Endocrinology. Despite these clear guidelines, GLP-1 RAs remain significantly underutilized, as …
Lung cancer disproportionately affects many groups across the United States, including ethnic minorities and poor, rural, and military service individuals, with higher incidence and mortality rates. While there are many factors contributing to this observation, clinicians can address lung cancer …
Although bariatric surgery is an intervention proven to offer well-established benefits for obesity, notable disparities remain in referral rates, access to care, and postoperative outcomes, particularly among racial, ethnic, and low-income populations. Moreover, implicit biases in the health care setting …
GLP-1 receptor agonists (GLP-1 RAs) are revolutionizing glycemic control for patients with type 2 diabetes (T2D), but with rising clinical complexity and diverse patient needs, a one-size-fits-all approach is insufficient. While every currently available GLP-1 RA is indicated for blood …
A major hurdle in managing type 2 diabetes (T2D) is a widespread gap in clinician awareness around the powerful, far-reaching benefits of GLP-1 receptor agonists (GLP-1 RAs). These innovative therapies help reduce the burden of cardiovascular, kidney, and metabolic (CKM) …